Ireland In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017

Introduction

”Ireland In Vitro Diagnostics Investment Opportunities, Analysis and Forecasts to 2017”, a new report by Global Markets Direct, provides key market data on the Ireland In Vitro Diagnostics market. The report provides value (USD million) data for each segment and sub-segment within seven market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture. The report also provides company shares and distribution shares data for each of the aforementioned market categories. The report is supplemented with global corporate-level profiles of the key market participants with information on key recent developments.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by Global Markets Direct’s team of industry experts.

Scope

- Market size and company share data for In Vitro Diagnostics market categories – Clinical Chemistry, Genetic Testing, Haematology, Histology And Cytology, Immuno Chemistry, Infectious Immunology and Microbiology Culture.
- Annualized market revenues (USD million) data for each of the segments and sub-segments within seven market categories. Data from 2003 to 2010, forecast forward for 7 years to 2017.
- 2010 company shares and distribution shares data for each of the seven market categories.
- Global corporate-level profiles of key companies operating within the Ireland In Vitro Diagnosticsmarket.
- Key players covered include F. Hoffmann-La Roche Ltd., Abbott Laboratories, Siemens Healthcare, Ortho-Clinical Diagnostics Inc., Beckman Coulter, Inc., bioMerieux S.A. and others.

Highlights

Reasons to buy

- Develop business strategies by identifying the key market categories and segments poised for strong growth.
- Develop market-entry and market expansion strategies.
- Design competition strategies by identifying who-stands-where in the Ireland In Vitro Diagnostics competitive landscape.
- Develop capital investment strategies by identifying the key market segments expected to register strong growth in the near future.
- What are the key distribution channels and what’s the most preferred mode of product distribution – Identify, understand and capitalize.

Report Highlights
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
Siemens Healthcare
Ortho-Clinical Diagnostics Inc.
Beckman Coulter, Inc.
bioMerieux S.A.
Bio-Rad Laboratories, Inc.
Sysmex Corporation
Becton, Dickinson and Company
Phadia AB
DiaSorin S.p.A
Alere Inc.
Thermo Fisher Scientific Inc.
PerkinElmer, Inc.
Qiagen N.V.
Gen-Probe Incorporated
Grifols, S.A.
HORIBA, Ltd.
DIAGNOSTICA STAGO, Inc.
Immucor, Inc.
Life Technologies Corporation
Danaher Corporation
Hologic, Inc.
[Studien Infos ausblenden]

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 7
1.2 List of Figures 9
2 Introduction 11
2.1 What is This Report About? 11
3 In Vitro Diagnostics In Ireland 12
3.1 In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, 2003-2017 12
3.2 In Vitro Diagnostics, Ireland, Company share (2009-2010) 18
4 Clinical Chemistry In Ireland 20
4.1 Clinical Chemistry Overall Revenue (2003-2017) 20
4.1.1 Clinical Chemisty Analyzers Revenue (2003-2017) 24
4.1.2 Urine Analysis Revenue (2003-2017) 28
4.2 Clinical Chemistry Distribution Share (2009-2010) 32
4.3 Clinical Chemistry, Ireland, Company share (2009-2010) 33
5 Genetic Testing In Ireland 35
5.1 Genetic Testing Overall Revenue (2003-2017) 35
5.2 Genetic Testing Distribution Share (2009-2010) 39
5.3 Genetic Testing, Ireland, Company share (2009-2010) 40
6 Haematology In Ireland 42
6.1 Haematology Overall Revenue (2003-2017) 42
6.1.1 Haematology Reagents Revenue (2003-2017) 46
6.1.2 Immunohaematology Revenue (2003-2017) 50
6.1.3 Haemostasis Revenue (2003-2017) 54
6.1.4 Haematology Rapid Tests Revenue (2003-2017) 58
6.1.5 Haematology Cell Counters Revenue (2003-2017) 62
6.2 Haematology Distribution Share (2009-2010) 66
6.3 Haematology, Ireland, Company share (2009-2010) 67
7 Histology And Cytology In Ireland 69
7.1 Histology And Cytology Overall Revenue (2003-2017) 69
7.2 Histology And Cytology Distribution Share (2009-2010) 73
7.3 Histology And Cytology, Ireland, Company share (2009-2010) 74
8 Immuno Chemistry In Ireland 76
8.1 Immuno Chemistry Overall Revenue (2003-2017) 76
8.1.1 Disease Specific Immunochemistry Revenue (2003-2017) 80
8.1.2 Drugs of Abuse / Toxicology Revenue (2003-2017) 84
8.1.3 Endocrinology Tests Revenue (2003-2017) 87
8.1.4 Therapeutic Drug Monitoring Revenue (2003-2017) 91
8.1.5 Immunochemistry Analyzers Revenue (2003-2017) 95
8.2 Immuno Chemistry Distribution Share (2009-2010) 99
8.3 Immuno Chemistry, Ireland, Company share (2009-2010) 100
9 Infectious Immunology In Ireland 102
9.1 Infectious Immunology Overall Revenue (2003-2017) 102
9.2 Infectious Immunology Distribution Share (2009-2010) 106
9.3 Infectious Immunology, Ireland, Company share (2009-2010) 107
10 Microbiology Culture In Ireland 109
10.1 Microbiology Culture Overall Revenue (2003-2017) 109
10.1.1 Microbiology Analyzers Revenue (2003-2017) 113
10.2 Microbiology Culture Distribution Share (2009-2010) 117
10.3 Microbiology Culture, Ireland, Company share (2009-2010) 118
11 Overview of Key Companies in Ireland In Vitro Diagnostics Market 119
11.1 F. Hoffmann-La Roche Ltd. 119
11.1.1 Company Overview 119
11.2 Abbott Laboratories 119
11.2.1 Company Overview 119
11.3 Siemens Healthcare 119
11.3.1 Company Overview 119
11.4 Ortho-Clinical Diagnostics Inc. 120
11.4.1 Company Overview 120
11.5 Beckman Coulter, Inc. 120
11.5.1 Company Overview 120
11.6 bioMerieux S.A. 120
11.6.1 Company Overview 120
11.7 Bio-Rad Laboratories, Inc. 121
11.7.1 Company Overview 121
11.8 Sysmex Corporation 121
11.8.1 Company Overview 121
11.9 Becton, Dickinson and Company 121
11.9.1 Company Overview 121
11.10 Phadia AB 122
11.10.1 Company Overview 122
11.11 DiaSorin S.p.A 122
11.11.1 Company Overview 122
11.12 Alere Inc. 122
11.12.1 Company Overview 122
11.13 Thermo Fisher Scientific Inc. 123
11.13.1 Company Overview 123
11.14 PerkinElmer, Inc. 123
11.14.1 Company Overview 123
11.15 Qiagen N.V. 123
11.15.1 Company Overview 123
11.16 Gen-Probe Incorporated 124
11.16.1 Company Overview 124
11.17 Grifols, S.A. 124
11.17.1 Company Overview 124
11.18 HORIBA, Ltd. 124
11.18.1 Company Overview 124
11.19 DIAGNOSTICA STAGO, Inc. 125
11.19.1 Company Overview 125
11.20 Immucor, Inc. 125
11.20.1 Company Overview 125
11.21 Life Technologies Corporation 125
11.21.1 Company Overview 125
11.22 Danaher Corporation 126
11.22.1 Company Overview 126
11.23 Hologic, Inc. 126
11.23.1 Company Overview 126
12 Financial Deals Landscape 127
12.1 Acquisition 127
12.1.1 PZ Cormay Acquires 98.62% Stake In Audit Diagnostics 127
12.2 Partnerships 128
12.2.1 Precision System Science Enters Into Co-Development Agreement With Biotrin International 128
12.2.2 Oxford Medical Diagnostics Enters Into Co-Marketing Agreement With V&F Analyse 129
12.2.3 Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 130
13 Recent Developments 131
13.1 Strategy And Business Planning 131
13.1.1 Dec 15, 2011: Covidien Plans Spin-Off Of Pharmaceuticals Business 131
13.1.2 Nov 16, 2011: DOCS Continues Expansion With Four New Offices In Europe 131
13.1.3 Nov 09, 2011: ICON And Empire Genomics Partner For Delivery Of Personalised Medicine Services 132
13.1.4 Sep 15, 2011: Covidien Announces R&D Center In China 132
13.1.5 May 20, 2011: Almac Opens New North American Headquarters 133
14 APPENDIX 134
14.1 Global Markets Direct Research Methodology 134
14.2 Definitions of Markets Covered in the Report 135
14.2.1 In Vitro Diagnostics 135
14.3 Secondary Research 145
14.4 Primary Research 145
14.5 Models 146
14.6 Forecasts 146
14.7 Expert Panel Validation 146
14.8 Currency Conversion 147
14.9 Contact Us 147
14.10 Disclaimer 147
[Inhaltsverzeichnis ausblenden]

1.1 List of Tables
Table 1: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, 2003-2017 13
Table 2: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, Historic, 2003-2010 15
Table 3: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 17
Table 4: In Vitro Diagnostics, Ireland, Company share by Revenue ($m), 2009-2010 19
Table 5: Clinical Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 21
Table 6: Clinical Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 23
Table 7: Clinical Chemisty Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 25
Table 8: Clinical Chemisty Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 27
Table 9: Urine Analysis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 29
Table 10: Urine Analysis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 31
Table 11: Clinical Chemistry, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 32
Table 12: Clinical Chemistry, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 34
Table 13: Genetic Testing, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 36
Table 14: Genetic Testing, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 38
Table 15: Genetic Testing, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 39
Table 16: Genetic Testing, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 41
Table 17: Haematology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 43
Table 18: Haematology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 45
Table 19: Haematology Reagents, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 47
Table 20: Haematology Reagents, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 49
Table 21: Immunohaematology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 51
Table 22: Immunohaematology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 53
Table 23: Haemostasis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 55
Table 24: Haemostasis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 57
Table 25: Haematology Rapid Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 59
Table 26: Haematology Rapid Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 61
Table 27: Haematology Cell Counters, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 63
Table 28: Haematology Cell Counters, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 65
Table 29: Haematology, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 66
Table 30: Haematology, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 68
Table 31: Histology And Cytology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 70
Table 32: Histology And Cytology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 72
Table 33: Histology And Cytology, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 73
Table 34: Histology And Cytology, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 75
Table 35: Immuno Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 77
Table 36: Immuno Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 79
Table 37: Disease Specific Immunochemistry, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 81
Table 38: Disease Specific Immunochemistry, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 83
Table 39: Drugs of Abuse / Toxicology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 85
Table 40: Drugs of Abuse / Toxicology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86
Table 41: Endocrinology Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 88
Table 42: Endocrinology Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 90
Table 43: Therapeutic Drug Monitoring, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 92
Table 44: Therapeutic Drug Monitoring, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 94
Table 45: Immunochemistry Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 96
Table 46: Immunochemistry Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 98
Table 47: Immuno Chemistry, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 99
Table 48: Immuno Chemistry, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 101
Table 49: Infectious Immunology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 103
Table 50: Infectious Immunology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 105
Table 51: Infectious Immunology, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 106
Table 52: Infectious Immunology, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 108
Table 53: Microbiology Culture, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 110
Table 54: Microbiology Culture, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 112
Table 55: Microbiology Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 114
Table 56: Microbiology Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 116
Table 57: Microbiology Culture, Ireland, Distribution Share by Revenue ($m), USD Actual, 2009-2010 117
Table 58: Microbiology Culture, Ireland, Company share by Revenue ($m), USD Actual 2009-2010 118
Table 59: PZ Cormay Acquires 98.62% Stake In Audit Diagnostics 127
Table 60: Precision System Science Enters Into Co-Development Agreement With Biotrin International 128
Table 61: Oxford Medical Diagnostics Enters Into Co-Marketing Agreement With V&F Analyse 129
Table 62: Trinity Biotech Enters Into Distribution Agreement With A. Menarini Diagnostics 130
Table 63: USD to Local Currency, Ireland, Average Actual Rate 2003-2010 147
1.2 List of Figures
Figure 1: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, 2003-2017 12
Figure 2: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, Historic, 2003-2010 14
Figure 3: In Vitro Diagnostics, Ireland, Overall Revenue ($m), USD Actual, Forecast, 2010-2017 16
Figure 4: In Vitro Diagnostics, Ireland, Company share (%), 2010 18
Figure 5: Clinical Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 20
Figure 6: Clinical Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 22
Figure 7: Clinical Chemisty Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 24
Figure 8: Clinical Chemisty Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 26
Figure 9: Urine Analysis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 28
Figure 10: Urine Analysis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 30
Figure 11: Clinical Chemistry, Ireland, Company share (%), 2010 33
Figure 12: Genetic Testing, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 35
Figure 13: Genetic Testing, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 37
Figure 14: Genetic Testing, Ireland, Company share (%), 2010 40
Figure 15: Haematology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 42
Figure 16: Haematology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 44
Figure 17: Haematology Reagents, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 46
Figure 18: Haematology Reagents, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 48
Figure 19: Immunohaematology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 50
Figure 20: Immunohaematology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 52
Figure 21: Haemostasis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 54
Figure 22: Haemostasis, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 56
Figure 23: Haematology Rapid Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 58
Figure 24: Haematology Rapid Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 60
Figure 25: Haematology Cell Counters, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 62
Figure 26: Haematology Cell Counters, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 64
Figure 27: Haematology, Ireland, Company share (%), 2010 67
Figure 28: Histology And Cytology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 69
Figure 29: Histology And Cytology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 71
Figure 30: Histology And Cytology, Ireland, Company share (%), 2010 74
Figure 31: Immuno Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 76
Figure 32: Immuno Chemistry, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 78
Figure 33: Disease Specific Immunochemistry, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 80
Figure 34: Disease Specific Immunochemistry, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 82
Figure 35: Drugs of Abuse / Toxicology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 84
Figure 36: Drugs of Abuse / Toxicology, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 86
Figure 37: Endocrinology Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 87
Figure 38: Endocrinology Tests, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 89
Figure 39: Therapeutic Drug Monitoring, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 91
Figure 40: Therapeutic Drug Monitoring, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 93
Figure 41: Immunochemistry Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 95
Figure 42: Immunochemistry Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 97
Figure 43: Immuno Chemistry, Ireland, Company share (%), 2010 100
Figure 44: Infectious Immunology, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 102
Figure 45: Infectious Immunology, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 104
Figure 46: Infectious Immunology, Ireland, Company share (%), 2010 107
Figure 47: Microbiology Culture, Ireland, Revenue ($m), USD Actual by Segment, Historic, 2003-2010 109
Figure 48: Microbiology Culture, Ireland, Revenue ($m), USD Actual by Segment, Forecast, 2010-2017 111
Figure 49: Microbiology Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Historic, 2003-2010 113
Figure 50: Microbiology Analyzers, Ireland, Revenue ($m), USD Actual by Sub-Segment, Forecast, 2010-2017 115
Figure 51: Microbiology Culture, Ireland, Company share (%), 2010 118
Figure 52: Global Markets Direct Methodology 134
[Tabellenverzeichnis ausblenden]